Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. (TIL) is a clinical-stage biopharmaceutical company pioneering tumor-infiltrating lymphocyte (TIL) therapies for solid tumor cancers. This page serves as the definitive source for official company announcements, research developments, and strategic updates in cell therapy innovation.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated news collection provides transparent access to Instil Bio's advancements in autologous TIL treatments and next-generation CoStAR-engineered therapies.
The repository includes press releases covering key areas: new clinical data disclosures, manufacturing facility expansions, intellectual property updates, and executive leadership changes. All content undergoes rigorous verification to ensure accuracy and compliance with financial reporting standards.
For consistent access to Instil Bio's latest developments, bookmark this page or subscribe to our news alert service. Regularly updated content supports informed decision-making for stakeholders tracking innovations in cancer immunotherapy.
Instil Bio initiated the DELTA-1 Phase 2 trial of ITIL-168 for advanced melanoma, receiving orphan drug and fast-track designations from the FDA. The company expanded its manufacturing in the UK and the California facility is expected to commence operations in H1 2022. Financially, as of December 31, 2021, Instil had $454.1 million in cash and equivalents. Their R&D expenses rose to $107.3 million for the year, reflecting a substantial increase from 2020. 2021 culminated in a net loss of $156.8 million, with significant operational developments expected in 2022.
Instil Bio (Nasdaq: TIL), a clinical-stage biopharmaceutical firm, will participate in the Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:10 a.m. ET. The panel discussion will focus on their tumor infiltrating lymphocyte (TIL) therapies aimed at treating patients with cancer. Interested parties can access a live webcast at this link, with an archived replay available for 90 days post-event. For more details, visit www.instilbio.com.
Instil Bio (NASDAQ: TIL) provided a corporate update and financial results for Q3 2021. Key highlights include the initiation of a Phase 2 trial (DELTA-1) for ITIL-168 in metastatic melanoma after receiving FDA IND clearance and Fast Track Designation. The company reported $20.4 million in cash and cash equivalents with $495 million in marketable securities as of September 30, 2021, enabling operations through 2023. Research and development expenses surged to $29.1 million for Q3 2021, compared to $4.9 million in 2020, reflecting ramped-up clinical efforts.
Instil Bio, Inc. (Nasdaq: TIL) announced the presentation of pre-clinical data for its CoStimulatory Antigen Receptor (CoStAR) platform at the SITC 2021. Key findings indicate that CoStAR significantly enhances the effector function of T cells when combined with tumor-reactive signals. Notably, the anti-FOLR1 CoStAR construct demonstrated over 40% transduction efficiency in primary ovarian cancer TILs. The company looks forward to initiating a Phase 1 study of ITIL-306 in early 2022, with the potential to reduce toxicity associated with high-dose IL-2.
Instil Bio, Inc. (Nasdaq: TIL) announced its participation in two investor conferences in November 2021. The Cowen 5th Annual IO Next Summit is scheduled for November 15, 2021, from 4:45 PM to 5:05 PM ET, with a live session link available. The Jefferies Global Healthcare Conference will be held on November 18, 2021, at 3:00 AM ET, also offering a live session link. An archived replay of both events will be accessible on the company's website for 90 days post-presentation. Instil is dedicated to developing TIL therapies targeting various cancers.
Instil Bio, Inc. (NASDAQ: TIL) presented a subset analysis of treatment outcomes for its TIL therapy at the ESMO Congress 2021. The analysis focused on 12 patients with checkpoint inhibitor-refractory advanced cutaneous melanoma. Among them, 58% achieved an objective response, with a median overall survival of 21.3 months, indicating the potential effectiveness of TIL therapy in difficult cases. The therapy demonstrated manageable side effects, primarily from the pre-treatment regimen. Instil aims to further explore TIL therapy in its upcoming Phase 2 DELTA-1 clinical trial.
Instil Bio (Nasdaq: TIL) has received FDA clearance for its DELTA-1 Phase 2 clinical trial of ITIL-168, aimed at treating patients with advanced melanoma. The trial will focus on patients who have relapsed after PD-1 inhibitors and will include expanded cohorts for those who faced toxicity or had unsatisfactory responses. Topline results are expected in 2023, with potential regulatory submissions for a biologics license application in the U.S. and a marketing authorization in Europe in 2024.
Instil Bio, Inc. (NASDAQ: TIL) announced its participation in two investor conferences this September. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 2:00 p.m. ET, featuring a fireside chat. Following that, Instil will present at Baird’s 2021 Virtual Global Healthcare Conference on September 14 at 5:30 p.m. ET. Live webcasts of these events will be available on the company’s website, with archived recordings accessible after the events.
Instil Bio (NASDAQ: TIL) reported significant clinical advancements in its second quarter 2021 update. In a compassionate use study for advanced melanoma, 67% of patients showed an objective response, with 19% achieving a complete response. The lead asset, ITIL-168, received orphan drug designation from the FDA. Instil is on track to initiate a Phase 2 trial for ITIL-168 in H2 2021 and a Phase 1 trial for ITIL-306 in H1 2022. Financially, cash reserves increased to $566.7 million, supporting operations through 2023.
Instil Bio (Nasdaq: TIL) announced its management will present an overview at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 9:30 a.m. ET. Interested parties can access a live webcast at here. Instil is focused on developing TIL therapies, advancing products like ITIL-168 and ITIL-306 for cancer treatment, particularly advanced melanoma and solid tumors.
